Evidence map›Paper›PMID 39030482›Full record

Trial reportBMC nephrology2024

A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLA

Mei Mei, Jun Zeng, Zhengyang Liu, Li Gong, Li Fang, Quan Hu, Shaofen Huang, Liyin Chai, Xinqing Chen, Haili Sun and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mei Mei *Department of Nephrology & Rheumatology, People's Hospital of Shapingba District, Chongqing University Shapingba Hospital, School of Medicine，Chongqing University, Chongqing, China.
Jun Zeng *Department of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China.
Zhengyang Liu *Department of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China.
Li GongDepartment of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China.
Li FangDepartment of Nephrology, The First Hospital Affiliated to Army Medical University, Chongqing, China.
Quan HuDepartment of Nephrology & Rheumatology, People's Hospital of Shapingba District, Chongqing University Shapingba Hospital, School of Medicine，Chongqing University, Chongqing, China.
Shaofen HuangDepartment of Nephrology & Rheumatology, People's Hospital of Shapingba District, Chongqing University Shapingba Hospital, School of Medicine，Chongqing University, Chongqing, China.
Liyin ChaiDepartment of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China.
Xinqing ChenDepartment of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China.
Haili SunDepartment of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China.
Sha XiangDepartment of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China.
Chaolin WenDepartment of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China.
Bingbing ShenDepartment of Nephrology, The First Hospital Affiliated to Army Medical University, Chongqing, China. shenbingbing@cqu.edu.cn.

Funding

Chongqing Science and health joint medical research general program 2019MSXM082
6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of hydroxychloroquine sulfate (HCQ) in the treatment of low risk phospholipase A

methodsA total of 110 patients with low risk PLA

resultsThe baseline data were comparable between the HCQ treatment group and the control group. At the end of the six-month follow-up period, the reductions in urine protein excretion and serum PLA

conclusionIn patients with low risk PLA

trial registrationThis study was registered in the Chinese Clinical Trial Registry (Registration No.: ChiCTR1900021757, Date of registration: 2019-03-08).

Indexed as

Glomerulonephritis, MembranousHydroxychloroquineReceptors, Phospholipase A2AdultAutoantibodiesFemaleHumansMaleMiddle AgedProteinuriaTreatment OutcomeAutoantibodiesHydroxychloroquinePLA2R1 protein, humanReceptors, Phospholipase A2Hydroxychloroquine sulfateLow riskPLA2R-associated membranous nephropathy

Identifiers

PMID39030482
PMCPMC11264965

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.